TrialDiabetes care2014

Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial.

Yoichiro Hirakawa et al.PubMed ↗Publisher ↗

No numbers read from the abstract.